SHINE Medical Technologies, received $150 million in funding from Deerfield Management Company, a healthcare investment firm, to support diagnostic and therapeutic medical isotope manufacturing, the company announced recently.

According to a release, the investment will be used for the construction of SHINE’s main production facility, which will start in the spring of 2019. It also will provide capital to ramp up operations prior to commencing commercial production of Mo-99, expected to start in 2021.

“We are excited to sign this deal as we begin construction of our Janesville production facility,” SHINE CEO Greg Piefer said in a statement. “Deerfield is a world-leading healthcare investment firm and is a strong partner that provides important institutional validation of our business.”

SHINE also announced it closed its Series B funding, raising more than $30 million of investments through private investors.